Onfekafusp Alfa

Summary

Onfekafusp Alfa (CHEMBL4298007) is a phase-3 clinical-stage protein; indicated across 4 conditions including soft tissue sarcoma and glioblastoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 4 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298007
Name	Onfekafusp Alfa
Type	Protein
Max phase	3

Also known as: Fibromun, L19tnf, Onfekafusp alfa, ONFEKAFUSP ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
soft tissue sarcoma	3	MONDO:0018078	EFO:1001968
glioblastoma	2	MONDO:0018177	EFO:0000519
melanoma	2	MONDO:0005105	EFO:0000756
paraganglioma	1	MONDO:0000448	EFO:1000453

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	9
PHASE1/PHASE2	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02938299	PHASE3	ACTIVE_NOT_RECRUITING	Neoadjuvant L19IL2/L19TNF- Pivotal Study
NCT04650984	PHASE3	UNKNOWN	A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
NCT04443010	PHASE1/PHASE2	RECRUITING	Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
NCT04733183	PHASE2	ACTIVE_NOT_RECRUITING	Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
NCT06284590	PHASE2	RECRUITING	Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
NCT06336291	PHASE2	ACTIVE_NOT_RECRUITING	A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
NCT07120984	PHASE2	NOT_YET_RECRUITING	A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
NCT07227350	PHASE2	NOT_YET_RECRUITING	L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
NCT07227870	PHASE2	NOT_YET_RECRUITING	L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07228442	PHASE2	NOT_YET_RECRUITING	L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT02076633	PHASE2	COMPLETED	Intratumoral Administration of L19IL2/L19TNF
NCT03779230	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
NCT04573192	PHASE1/PHASE2	UNKNOWN	A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
NCT05329792	PHASE2	UNKNOWN	L19IL2/L19TNF in Skin Cancer Patients
NCT04032964	PHASE1	UNKNOWN	Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
NCT05304663	PHASE1	WITHDRAWN	Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).